EDB Announces General Availability of BigAnimal, PostgreSQL Database in the Cloud
2.11.2021 15:00:00 EET | Business Wire | Press release
EDB, a leading contributor to PostgreSQL®, today announced the general availability of its BigAnimal™ offering, the first fully-managed PostgreSQL database in the cloud with compatibility for Oracle database technology. Built and backed by the world’s largest roster of PostgreSQL engineers, BigAnimal is for enterprises looking to deploy their most demanding databases into the cloud.
“BigAnimal was built in direct response to what our customers told us was missing from existing cloud Postgres offerings,” said EDB president and CEO, Ed Boyajian. “These improvements aren’t incremental - they’re transformational. We’ve made no compromises. This means you get fanatical attention from the biggest team in Postgres, native compatibility with Oracle database technology, and extreme high availability. And we run it all inside your cloud account.”
Accelerate Business with the Best Cloud PostgreSQL
Customers who are building serious cloud applications are realizing that they can’t get what they need from the basic PostgreSQL offerings available today. Without the transparency, control, and performance tuning required for their most demanding workloads, they are held back from moving fully into the cloud. BigAnimal responds to these needs by giving organizations granular control over the database within their own accounts and all the enterprise PostgreSQL capabilities EDB has been developing over the past 15 years - while being fully managed by EDB.
Specifically, with BigAnimal, enterprises will experience the following benefits:
- Partner with PostgreSQL builders. For over a decade, PostgreSQL users have counted on EDB for their on-premises deployments. Now with BigAnimal, users can also rely on unequaled support from EDB’s world-class PostgreSQL experts.
- Migrate applications on Oracle databases to PostgreSQL on Azure with little to no changes needed. With BigAnimal, customers can reduce costs, time, and risks when migrating workloads from legacy Oracle databases to cloud environments. BigAnimal’s deep compatibility with Oracle database technology and comprehensive migration tools address a critical need for enterprises who want to move quickly without leaving behind all their legacy database investments in code, skill sets, and resources.
- Increase transparency and control of their cloud PostgreSQL. BigAnimal runs in a customer’s cloud account, allowing them to closely manage, secure, and optimize their PostgreSQL along with their other infrastructure according to their business needs and spend commitments. BigAnimal also gives users an unprecedented level of control over their PostgreSQL with superuser access to precisely tweak database internals.
- Minimize complexity with the same PostgreSQL everywhere. EDB Postgres users can expect a uniform database experience, from EDB Postgres on premises to BigAnimal on Azure. This includes the ability to use their existing PostgreSQL skill sets, incorporate the database into their DevOps pipelines, and leverage EDB Postgres Advanced enterprise capabilities, such as enhanced security, performance management, and compatibility with Oracle database technology. With support for license portability, EDB also allows customers to easily deploy PostgreSQL whenever, wherever their business requires.
According to Carl Olofson, research vice president, Data Management Software, IDC: “In 2021, we saw a significant rise in cloud infrastructure spend and expect it to soon surpass non-cloud infrastructure. With this growing reliance on cloud platforms, many companies don’t have the in-house skills to deploy, manage, and optimize their databases. Considering EDB’s long track record of building and supporting Postgres, companies have a strong option for transitioning smoothly and optimizing their cloud database operations.”
For more information about EDB and BigAnimal and to sign up for a trial, please visit www.biganimal.com.
EnterpriseDB, EDB and Postgres Enterprise Manager are registered trademarks of EnterpriseDB Corporation. EDB Postgres and BigAnimal are trademarks of EnterpriseDB Corporation.
Postgres, PostgreSQL, and the Slonik Logo are trademarks or registered trademarks of the PostgreSQL Community Association of Canada, and used with their permission.
About EDB
PostgreSQL is increasingly the database of choice for organizations looking to boost innovation and accelerate business. EDB’s enterprise-class software extends PostgreSQL, helping our customers get the most out of it both on premises and in the cloud. And our 24x7 global support, professional services, and training help our customers control risk, manage costs, and scale efficiently. With 16 offices worldwide, EDB serves over 5,000 customers, including leading financial services, government, media and communications, and information technology organizations. To learn about PostgreSQL for people, teams, and enterprises, visit EDBpostgres.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211102005218/en/
Contact information
Kate Connors
PAN Communications
781-820-3767
enterprisedb@pancomm.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release
OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202613.6.2026 00:31:00 EEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 19:36:00 EEST | Press release
IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
